These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29425101)

  • 1. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
    Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
    J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Chong H; Zhu Y; Yu D; He Y
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
    Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
    J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.
    Hu Y; Yu W; Geng X; Zhu Y; Chong H; He Y
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
    Zhang X; Ding X; Zhu Y; Chong H; Cui S; He J; Wang X; He Y
    AIDS; 2019 Jan; 33(1):1-11. PubMed ID: 30096076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
    Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
    PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.